|
11 Apr 2021 |
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
|
|
11 Apr 2021 |
Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma
|
|
09 Apr 2021 |
ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
|
|
09 Apr 2021 |
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
|
|
09 Apr 2021 |
Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor
|
|
08 Apr 2021 |
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
|
|
07 Apr 2021 |
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
|
|
07 Apr 2021 |
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
|
|
07 Apr 2021 |
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
|
|
07 Apr 2021 |
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
|
|
07 Apr 2021 |
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
|
|
06 Apr 2021 |
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
|
|
06 Apr 2021 |
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
|
|
02 Apr 2021 |
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial
|
|
02 Apr 2021 |
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
|
|
02 Apr 2021 |
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
|
|
02 Apr 2021 |
FDA Grants Breakthrough Therapy Designation for Taiho Oncology’s Futibatinib for Treatment of Advanced Cholangiocarcinoma
|
|
31 Mar 2021 |
European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
|
|
31 Mar 2021 |
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
|
|
31 Mar 2021 |
Amgen to Acquire Rodeo Therapeutics Corporation
|
|
30 Mar 2021 |
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
|
|
30 Mar 2021 |
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
|
|
30 Mar 2021 |
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
|
|
30 Mar 2021 |
Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
|
|
30 Mar 2021 |
Daiichi Sankyo Initiates Phase 1 Trial for Nafamostat Inhalation Formulation (DS-2319) in Japan
|
